Whalesbook
📉 The Financial Deep Dive
Shaily Engineering Plastics Limited has unveiled robust financial results for Q3 FY26 and the nine months ended December 31, 2025, marked by significant top-line and bottom-line growth, primarily propelled by its burgeoning healthcare segment.
The Numbers:
Consolidated revenues for the third quarter of FY26 reached ₹250.5 Cr, an impressive 27% increase year-over-year (YoY) from ₹197.6 Cr in Q3 FY25. For the nine-month period (9M) of FY26, revenues grew by 32% YoY to ₹753.8 Cr compared to ₹569.0 Cr in 9M FY25. Profit After Tax (PAT) demonstrated substantial momentum, with Q3 FY26 PAT at ₹37.4 Cr (up 48% YoY) and 9M FY26 PAT at ₹129.8 Cr (up an exceptional 101% YoY). EBITDA also surged, growing 43% YoY to ₹66.4 Cr in Q3 FY26 and 101% YoY to ₹218.4 Cr in 9M FY26.
The Quality:
Profitability margins expanded significantly. Consolidated EBITDA margin increased by 310 basis points (bps) YoY to 26.5% in Q3 FY26, and the PAT margin improved by 220 bps YoY to 14.9%. For the nine months, the EBITDA margin expanded by an impressive 730 bps to 29.0% and the PAT margin by 590 bps to 17.2%. The healthcare segment was the primary growth driver, with its revenue increasing by a remarkable 139% YoY to ₹104.3 Cr in Q3 FY26. While the industrial segment saw a healthy 36% YoY revenue growth for 9M FY26, the consumer segment's revenue declined by 13% YoY in Q3 FY26. Cash flow from operations for H1 FY26 stood at ₹98.4 Cr, while net cash from investing activities was -₹89.6 Cr, indicating ongoing capital expenditure for expansion.
Strategic Expansion & Outlook:
The company is making significant strategic moves, especially in its healthcare division. It has onboarded two new customers in the GLP-1 segment and signed two new contracts for pen injector manufacturing, highlighting strong demand in this high-growth vertical. A key development is the planned establishment of a new manufacturing facility in Abu Dhabi for medical devices, involving an investment of AED 130-150 million. This facility, expected to be operational by Q4 FY28, will boast a capacity of approximately 75 million pen injectors per annum. This expansion aims to enhance proximity to international customers and capitalize on the global GLP-1 opportunity. The appointment of Mr. Joe Kam as COO (Healthcare) further bolsters the leadership for this global push.
Balance Sheet & Ratios:
Consolidated total assets stood at ₹1,054.6 Cr as of September 2025, up from ₹932.6 Cr in March 2025, with Property, Plant, and Equipment (PPE) increasing to ₹513.9 Cr. Total equity grew to ₹635.5 Cr. Consolidated borrowings were ₹189.1 Cr as of Sept-25, resulting in a Debt-to-Equity ratio of 2.0. This leverage is a point to monitor, though the company's strong profitability is evident in its key ratios. Consolidated Return on Capital Employed (RoCE) stood at a robust 38.4% and Return on Equity (RoE) at 29.1% as of December 2025.
🚩 Risks & Forward View:
The primary risk to monitor is the company's Debt-to-Equity ratio of 2.0, which indicates a relatively high level of financial leverage. The decline in the consumer segment also warrants attention. Investors should watch for the execution progress of the Abu Dhabi facility, continued growth acceleration in the healthcare segment, and the company's ability to service its debt effectively, especially as it undertakes significant capital expenditure.
The company's strategic focus on the high-growth medical device and drug delivery segments, coupled with its global manufacturing expansion, positions it for sustained long-term growth. The ability to scale up operations and maintain margin expansion will be key.